Mandy M. Law

Mandy M. Law

Auto-generated profile, based on publicly available information

Mandy M. Law

Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2021 in Nephrology
Verified
Journal Article
Closed access
PDF file
MLMandy M. Law
Mandy M. Law
JSJoel D. Smith
Joel D. Smith
HSHans G. Schneider
Hans G. Schneider
SWScott Wilson
Scott Wilson

19 June 2023 in Kidney Medicine
Verified
Journal Article
Open access
MLMandy M. Law
Mandy M. Law
STSven-Jean Tan
Sven-Jean Tan
MWMichael C.G. Wong
Michael C.G. Wong
NTNigel D. Toussaint
Nigel D. Toussaint
Management of atrial fibrillation (AF) is a clinical conundrum in people with kidney failure. Stroke risk is disproportionately high, but clinicians have a limited armamentarium to improve outcomes in this population in whom there is a concurrently high bleeding risk. Direct oral anticoagulants may have a superior benefit–risk profile compared with vitamin K antagonists in people on hemodialysis. Although research has predominantly focused on identifying a safe and effective oral anticoagulation option to reduce stroke risk in people with kidney failure (and predominantly those on hemodialysis), it remains uncertain how clinicians discriminate between people who would derive net clinical benefit as opposed to net harm. The recommended CHA2DS2-VASc score cutoffs provide poor discriminatory value, and there is an urgent need to identify robust markers of thromboembolic risk in kidney failure.

27 April 2024 in Case Reports in Nephrology
Verified
Journal Article
Open access
PDF file
AKA. Krelle
A. Krelle
SPSarah Anna Lucy Price
Sarah Anna Lucy Price
MLM. M. Law
M. M. Law
SKSevastjan Kranz
Sevastjan Kranz
PSP. Shamdasani
P. Shamdasani
PCP. Champion de Crespigny
P. Champion de Crespigny
Thrombotic microangiopathy (TMA) reflects a syndrome of endothelial injury characterised by microangiopathic haemolytic anaemia (nonimmune), thrombocytopenia, and often end-organ dysfunction. TMA disorders are well-recognised in kidney transplant recipients, often due to an underlying genetic predisposition related to complement dysregulation, or de novo due to infection, immunosuppression toxicity, or antibody-mediated rejection. In pregnancy, TMA disorders are most commonly due to severe pre-eclampsia or HELLP, but may also be due to thrombotic thrombocytopenic purpura (TTP) or complement-mediated (atypical) haemolytic uremic syndrome (aHUS). Complement dysregulation is being recognised as playing a role in the development of preeclampsia and HELLP syndrome in addition to aHUS. Due to overlapping clinical and laboratory features, diagnosis can be difficult and delays in treatment can be life-threatening for both mother and fetus. This report describes a 32 year-old female who had two successive wanted pregnancies. The first pregnancy was terminated at 22 weeks gestation due to presumed severe preeclampsia and fetal growth restriction in the context of known chronic kidney failure due to reflux nephropathy. A living-related kidney transplant was performed to improve the chances of pregnancy resulting in a live birth. A subsequent pregnancy was complicated by progressive kidney impairment and hypertension at 22 weeks gestation. Kidney biopsy showed TMA, but the etiology was unclear. This report highlights the diagnostic dilemma of TMA in a pregnant kidney transplant recipient and a role for the anti-C5 terminal complement blockade monoclonal antibody eculizumab, in pregnancy-associated TMA, especially at a peri-viable gestation.

10 February 2025 in Nephrology
Verified
Journal Article
Closed access
MLMandy M. Law
Mandy M. Law
STSven‐Jean Tan
Sven‐Jean Tan
MWMichael C. G. Wong
Michael C. G. Wong
NTNigel D. Toussaint
Nigel D. Toussaint

17 August 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
KJKushani Jayasinghe
Kushani Jayasinghe
RTRigan Tytherleigh
Rigan Tytherleigh
SBStephanie Best
Stephanie Best
SBSimon Bodek
Simon Bodek
PBPaula Bussa
Paula Bussa
CQCatherine Quinlan
Catherine Quinlan
Key Points: We evaluated a hub and spoke mainstreaming model to enable nephrologists to order genomic tests independently in their clinic across the state of Victoria. Over 1000 tests were ordered, with the diagnostic yield remaining similar regardless of ordered by local nephrologists or tertiary genomics services. A mainstreaming model proved feasible, scalable, and clinically effective, offering a practical framework for integrating genomics to routine kidney care. Background: Genomic testing has substantial diagnostic and clinical value in nephrology, yet integrating testing into routine care requires service-level changes to ensure timely and equitable access. Methods: We conducted an observational cohort study at four tertiary centers, with a pragmatic, quasi-experimental design to evaluate evidence-informed, service-level interventions to make genomic testing more accessible and routinely embedded within nephrology practice. We implemented a hub and spoke model which provided nephrologists with training, practical resources, and regular case-based discussions, to support test ordering and interpretation within their own clinics. Laboratory audits (June 2021–July 2024) evaluated how public reimbursement and implementation interventions influenced testing patterns. Three periods were compared: prefunding, postfunding, and postintervention. Results: Across the study period, 1028 genomic tests were ordered (63% adults, 37% children; median age 32 years). Results were available for 1014 tests, with an overall diagnostic yield of 34%, which remained stable across all time points. The diagnostic yield was similar regardless of whether testing occurred at tertiary genomics services (249 of 772, 32%) or via local nephrologists (92 of 242, 38%). The number of unique providers ordering tests was higher (T1: 37, T2: 69, T3: 87). The proportion of testing in mainstream nephrology settings rose from 23% to 74%, while absolute testing numbers in multidisciplinary clinics remained consistent over the study period. Conclusion: Mainstreaming genomic testing in nephrology was feasible, scalable, and clinically effective. This model was associated with better access without compromising diagnostic yield and provides a practical framework for integrating genomic medicine into routine kidney care.